Elanix Biotechnologies AG | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR0.58 |
Market Cap |
EUR22.48 M |
Shares Outstanding |
7.78 M |
Public Float |
- |
Address |
Hohenstaufenstrasse 1 Wiesbaden Hessen 65189 Germany |
Employees | - |
Website | http://www.elanix-biotechnologies.de |
Updated | 07/08/2019 |
Elanix Biotechnologies AG operates as a holding company, which engages in the development and marketing of progenitor cell-based products for acute wound care, as well as dermatological and gynecological applications. It operates through the Regenerative Medicine and Cosmetic Ointments business segments. The Regenerative Medicine segment offers skin dressings made from progenitor skin fibroblasts to provide protection and accelerated healing for burns and reconstructive surgery. |